Sino Biopharmaceutical (1177.HK): Strong downward momentum

After the release of the 3Q result, the stock slumped 10%.

Charts (3)

Sino Biopharmaceutical (1177), a pharmaceutical company, reported that 9-month underlying net income fell 17.9% on year to 2.29 billion yuan on revenue of 18.13 billion yuan, down 6.2%. After the release of the 3Q result, the stock slumped 10%. 

Besides, Citibank cut the company target prices from HK$12.8 to HK$11.60. 

From a technical point of view, the stock broke below a rising trend line from June 2019. The RSI broke below its oversold level at 30, suggesting a strong downward momentum. The declining 20-day moving average is also acting as key resistance now. Bearish readers could set the resistance level at HK$7.60, while resistance levels would be located at HK$6.15 and HK$6.25.

Source: GAIN Capital, TradingView

More from Equities


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.